Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Risk stratification of MGUS and SMM: current and future perspectives

Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, shares insights into a session held at this year’s meeting which focused on risk stratification in smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS). Dr Beksac highlights the importance measuring the free light chain (FLC) ratio and M protein when stratifying patients at risk of disease progression. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.